Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Participants with higher OPG serum levels were older, had lower eGFR, more frequently had diabetes mellitus or CVD at baseline, had higher blood pressure, and used more medications (Table 2).Demographics and clinical parameters at baseline according to osteoprotegerin (OPG) quintiles in the GCKD cohort (n = 4 246)Osteoprotegerin/(pmol·L−1)CharacteristicsQ1 (≤4.8)Q2 (>4.8: ≤5.9)Q3 (>5.9: ≤7.1)Q4 (>7.1: ≤8.7)Q5 (>8.7)n/%850 (20.0)849 (20.0)849 (20.0)850 (20.0)848 (20.0)Age/years52.2 ± 13.456.6 ± 12.161.9 ± 9.964.5 ± 8.766.2 ± 8.4Male, n/%568 (13.4)535 (12.6)534 (12.6)494 (11.6)478 (11.3)Systolic BP/mmHg134.8 ± 17.6137.6 ± 18.8138.8 ± 19.8143.2 ± 22.0142.7 ± 22.1Diastolic BP/mmHg80.7 ± 11.480.4 ± 11.679.3 ± 11.978.7 ± 11.876.4 ± 12.3BMI/(kg·m: 2)29.2 ± 5.429.7 ± 6.030.1 ± 6.230.7 ± 6.329.7 ± 5.9Diabetes, n/%183 (4.3)223 (5.3)289 (6.8)389 (9.2)438 (10.3)Previous CVD, n/%150 (3.5)163 (3.8)223 (5.3)278 (6.5)309 (7.3)Smoking Never, n/%340 (8.0)334 (7.9)335 (7.9)341 (8.1)349 (8.2) Former, n/%344 (8.1)348 (8.2)385 (9.1)387 (9.1)371 (8.8) Current, n/%164 (3.9)165 (3.9)127 (3.0)120 (2.8)124 (2.9) Unknown, n/%2 (0.0)2 (0.0)2 (0.0)2 (0.0)4 (0.1)eGFR/(mL·min: 1 per 1.73 m2)53.8 ± 20.351.5 ± 17.847.4 ± 16.346.0 ± 15.742.6 ± 14.5UACR/(mg·g: 1)72.4 (11.8 to 498.0)54.3 (9.4 to 420.5)31.3 (8.3 to 308.5)46.8 (9.7 to 352.5)62.6 (10.8 to 351.5)hsCRP/(mg·L−1)1.8 (0.8 to 4.0)2.0 (0.9 to 4.7)2.4 (1.1 to 5.4)2.5 (1.2 to 5.2)3.0 (1.4 to 6.7)Serum albumin/(mg·L−1)39.2 (36.7 to 41.3)38.9 (36.6 to 41.0)39.0 (36.5 to 41.0)38.3 (36.1 to 40.6)37.8 (35.3 to 40.2)LDL cholesterol/(mg·dL−1)115.1 (90.9 to 144.7)115.8 (92.8 to 147.1)114.3 (89.4 to 141.2)112.0 (87.0 to 141.3)106.6 (81.5 to 137.5)HDL cholesterol/(mg·dL−1)46.6 (37.9 to 59.4)48.2 (39.1 to 59.7)47.3 (39.2 to 59.8)49.0 (39.7 to 60.8)49.2 (39.3 to 63.4)RASi, n/%732 (17.2)715 (16.8)731 (17.2)721 (17.0)701 (16.5)Statins, n/%353 (8.4)383 (9.1)423 (10.0)461 (10.9)439 (10.4)Beta blocker, n/%391 (9.3)415 (9.8)506 (12.0)532 (12.8)516 (12.2)Thrombocyte aggregation inhibitors, n/%194 (4.6)260 (6.2)309 (7.3)368 (8.7)384 (9.1)Aldosterone antagonists, n/%58 (1.4)54 (1.3)67 (1.6)80 (1.9)84 (2.0)Vitamin D therapy, n/%260 (6.2)239 (5.7)255 (6.1)272 (6.5)294 (6.9)Continuous variables are presented as the mean and standard deviation or median and interquartile range.
Source: Characteristics of the study cohort. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
During follow-up, patients were subjected to yearly interviews by trained personnel in alternating phone visits and face-to-face interactions.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort
Study design awaiting verification · Bone Research · 2023
Original publication title
Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Mineral and bone disorder (MBD) in chronic kidney disease (CKD) is tightly linked to cardiovascular disease (CVD). In this study, we aimed to compare the prognostic value of nine MBD biomarkers to determine those associated best with adverse cardiovascular (CV) outcomes and mortality. In 5 217 participants of the German CKD (GCKD) study enrolled with an estimated glomerular filtration rate (eGFR) between 30 to 60 mL·min−1 per 1.73 m2 or overt proteinuria, serum osteoprotegerin (OPG), C-terminal fibroblast growth factor-23 (FGF23), intact parathyroid hormone (iPTH), bone alkaline phosphatase (BAP), cross-linked C-telopeptide of type 1 collagen (CTX1), procollagen 1 intact N-terminal propeptide (P1NP), phosphate, calcium, and 25-OH vitamin D were measured at baseline.
Participants with missing values among these parameters (n = 971) were excluded, leaving a total of 4 246 participants for analysis. During a median follow-up of 6.5 years, 387 non-CV deaths, 173 CV deaths, 645 nonfatal major adverse CV events (MACEs) and 368 hospitalizations for congestive heart failure (CHF) were observed. OPG and FGF23 were associated with all outcomes, with the highest hazard ratios (HRs) for OPG. In the final Cox regression model, adjusted for CV risk factors, including kidney function and all other investigated biomarkers, each standard deviation increase in OPG was associated with non-CV death (HR 1.76, 95% CI: 1.35 to 2.30), CV death (HR 2.18, 95% CI: 1.50 to 3.16), MACE (HR 1.38, 95% CI: 1.12 to 1.71) and hospitalization for CHF (HR 2.05, 95% CI: 1.56 to 2.69).
Out of the nine biomarkers examined, stratification based on serum OPG best identified the CKD patients who were at the highest risk for any adverse CV outcome and mortality.
Authors’ abstract
Mineral and bone disorder (MBD) in chronic kidney disease (CKD) is tightly linked to cardiovascular disease (CVD). In this study, we aimed to compare the prognostic value of nine MBD biomarkers to determine those associated best with adverse cardiovascular (CV) outcomes and mortality. In 5 217 participants of the German CKD (GCKD) study enrolled with an estimated glomerular filtration rate (eGFR) between 30 to 60 mL·min−1 per 1.73 m2 or overt proteinuria, serum osteoprotegerin (OPG), C-terminal fibroblast growth factor-23 (FGF23), intact parathyroid hormone (iPTH), bone alkaline phosphatase (BAP), cross-linked C-telopeptide of type 1 collagen (CTX1), procollagen 1 intact N-terminal propeptide (P1NP), phosphate, calcium, and 25-OH vitamin D were measured at baseline.
Participants with missing values among these parameters (n = 971) were excluded, leaving a total of 4 246 participants for analysis. During a median follow-up of 6.5 years, 387 non-CV deaths, 173 CV deaths, 645 nonfatal major adverse CV events (MACEs) and 368 hospitalizations for congestive heart failure (CHF) were observed. OPG and FGF23 were associated with all outcomes, with the highest hazard ratios (HRs) for OPG. In the final Cox regression model, adjusted for CV risk factors, including kidney function and all other investigated biomarkers, each standard deviation increase in OPG was associated with non-CV death (HR 1.76, 95% CI: 1.35 to 2.30), CV death (HR 2.18, 95% CI: 1.50 to 3.16), MACE (HR 1.38, 95% CI: 1.12 to 1.71) and hospitalization for CHF (HR 2.05, 95% CI: 1.56 to 2.69).
Out of the nine biomarkers examined, stratification based on serum OPG best identified the CKD patients who were at the highest risk for any adverse CV outcome and mortality.
Publication and source details
Original title: Association of mineral and bone biomarkers with adverse cardiovascular outcomes and mortality in the German Chronic Kidney Disease (GCKD) cohort
Katharina Charlotte Reimer; Jennifer Nadal; Heike Meiselbach; Matthias Schmid; Ulla T. Schultheiss; Fruzsina Kotsis; Helena Stockmann; Nele Friedrich; Matthias Nauck; Vera Krane; Kai-Uwe Eckardt; Markus P. Schneider; Rafael Kramann; Jürgen Floege; Turgay Saritas; on behalf of the GCKD study investigatorsSchifferMario13ProkoschHans-Ulrich13BärthleinBarbara13BeckAndreas13ReisAndré13EkiciArif B.13BeckerSusanne13Alberth-SchmidtUlrike13WeigelAnke13MarschallSabine13ScheflerEugenia13WalzGerd14KöttgenAnna14KotsisFruzsina14MederSimone14MitschErna14ReinhardUrsula14SchaeffnerElke15Baid-AgrawalSeema15TheisenKerstin15Schmidt-OttKai16ZeierMartin17SommererClaudia17AykacMehtap17WolfGunter18PaulRainer18Börner-KleinAntje19BauerBritta19RaschenbergerJulia20KolleritsBarbara20ForerLukas20SchönherrSebastian20WeissensteinerHansi20OefnerPeter21GronwaldWolfram21
Bone Research · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.https://doi.org/10.13039/501100003042Else Kröner-Fresenius-Stiftung (Else Kroner-Fresenius Foundation)2022_EKES.03Saritas Turgay German Society of Internal Medicine 361357https://doi.org/10.13039/501100002347Bundesministerium für Bildung und Forschung (Federal Ministry of Education and Research)01ZX1912B01ZX1912BFKZ 01ER 0804, 01ER 0818, 01ER 0819, 01ER 0820, and 01ER 0821Schultheiss Ulla T. Kotsis Fruzsina Eckardt Kai-Uwe KfH (Kuratorium für Heimdialyse und Nierentransplantation e.V.: Stiftung Präventivmedizin: no grant numberhttps://doi.org/10.13039/501100001659Deutsche Forschungsgemeinschaft (German Research Foundation)322900939Floege JürgenRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T05:57:47.045873+00:00
DOI: 10.1038/s41413-023-00291-8 · PMC10587182